NCT01857544Unknown4 期
Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Complete anatomic resolution of macular edema following central retinal vein occlusion (CRVO) as measured by Optical Coherence Tomography (OCT)
研究概览
简要总结
The purpose of this study is determine the number of patients with complete resolution of macular edema secondary to central retinal vein occlusion following 6 monthly injections of Aflibercept.
详细描述
Twenty (20) consented participant who meet the inclusion criteria will be enrolled to be followed for 6 months. All subjects will receive monthly 2.0 mg intravitreal aflibercept injections.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A patient must meet the following criteria to be eligible for inclusion in the study:
- •Age >18 years
- •Documented macular edema following central retinal vein occlusion
- •Currently receiving treatment with intravitreal anti-VEGF therapy initiated at least 3 months months previously
- •Documented intravitreal treatment with ranibizumab 0.5 mg (at least 3 doses, each one month apart) or bevacizumab 1.25 mg (at least 3 doses, each one month apart)
- •Presence of persistent macular edema (defined as any of the following):
- •central foveal thickness (CFT) of > 300 microns by spectral-domain OCT
- •presence of any intraretinal or subretinal fluid
- •Receipt of intravitreal anti-VEGF injections more frequently than once per month
- •Willingness and ability to comply with clinic visits and study-related procedures
- •Ability to provide signed informed consent
排除标准
- •Prior vitrectomy in the study eye
- •Concurrent retinal vascular disease in the study eye that could compromise visual acuity or contribute to macular edema (e.g. diabetic retinopathy, age-related macular degeneration)
- •Any concurrent intraocular condition in the study eye (e.g. diabetic retinopathy, advanced glaucoma) that, in the opinion of the investigator, could either
- •require medical or surgical intervention during the 6-month study period to prevent or treat visual loss; or,
- •if allowed to progress untreated, contribute to loss of at least 2 Snellen equivalent lines of best corrected visual acuity over the 6 month study period
- •Active intraocular inflammation (grade trace or above) in the study eye, or history of idiopathic or autoimmune-associated uveitis in either eye
- •Current vitreous hemorrhage in the study eye
- •Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
- •Intraocular surgery (including cataract surgery) in the study eye within 60 days preceding baseline
- •Systemic anti-VEGF treatment within the last 3 months prior to screening
- •Prior intravitreal aflibercept injection in the study eye
- •Macular laser photocoagulation within 4 months of screening
- •Intravitreal or periocular corticosteroid within 4 months of screening
- •Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with ocular antihypertensive medication)
- •Allergy to fluorescein, povidone iodine (Betadine) or aflibercept
- •Participation in a study of an investigational drug or device within 30 days prior to potential enrollment into the study
- •Patients with cognitive dysfunction such as dementia, Alzheimer's disease or any other neuro-degenerative disorder.
- •Pregnant or breast-feeding women
- •Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly)
- •Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
研究组 & 干预措施
Aflibercept 2.0mg
Experimental
Single arm - Intravitreal Aflibercept 2.0mg, 0.05 milliliters, monthly for 6 months.
干预措施: Aflibercept (Drug)
结局指标
主要结局
Complete anatomic resolution of macular edema following central retinal vein occlusion (CRVO) as measured by Optical Coherence Tomography (OCT)
时间窗: From baseline to Month 6
次要结局
- Mean change in best-corrected visual acuity (BCVA)(Month 6)
- Proportion of patients with gain or loss of 5, 10, and 15 letters in BCVA(Month 6)
- Number and severity of adverse events(6 month-period)
- Extent of reduction in macular thickness(Month 6)
- Extent of reduction in macular volume(Month 6)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment RepairRetinal Detachment With Multiple Breaks, Unspecified EyeProliferative VitreoretinopathyNCT04580147M. Ali Khan, MD150
已完成
3 期
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)Nonproliferative Diabetic RetinopathyNCT02718326Regeneron Pharmaceuticals402
Unknown
1 期
Treatment for Presumed Ocular HistoplasmosisOcular HistoplasmosisNCT01790893John Kitchens, MD40
已完成
3 期
Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular EdemaDiabetic Macular EdemaNCT01363440Regeneron Pharmaceuticals466
已完成
4 期
IAI for Persistent DME After Treatment With Bevacizumab And RanibizumabDiabetic Macular EdemaNCT03340610Southeast Retina Center, Georgia30